Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 57,300 shares, a drop of 9.0% from the July 31st total of 63,000 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily trading volume, of 32,300 shares, the short-interest ratio is currently 1.8 days.

Cocrystal Pharma Stock Down 3.3 %

Shares of COCP traded down $0.06 during mid-day trading on Tuesday, hitting $1.74. The stock had a trading volume of 17,311 shares, compared to its average volume of 22,127. Cocrystal Pharma has a fifty-two week low of $1.33 and a fifty-two week high of $3.10. The company has a market cap of $17.70 million, a PE ratio of -1.00 and a beta of 1.41. The company’s fifty day simple moving average is $2.08 and its two-hundred day simple moving average is $1.88.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). Equities analysts expect that Cocrystal Pharma will post -1.94 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright dropped their target price on Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, August 22nd.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.